sub:assertion {
d:DB00176 dv:ddi-interactor-in dr:DB00176_DB00458 .
d:DB00458 dv:ddi-interactor-in dr:DB00176_DB00458 .
dr:DB00176_DB00458 dcterms:identifier "drugbank_resource:DB00176_DB00458" ;
dcterms:title "DDI between Fluvoxamine and Imipramine - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Fluvoxamine and Imipramine - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB00458]"@en .
}